{"filing":{"accession_number":"0001493152-26-038446","cik":"0000109657","ticker":"GTBP","company_name":"GT Biopharma, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226038446/form8-k.htm"},"events":[{"id":27971,"run_id":25548,"accession_number":"0001493152-26-038446","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses results of GT Biopharma's Annual Meeting of Stockholders held on August 14, 2026, under Item 5.07. Six proposals were voted upon: election of four directors, ratification of auditors (Weinberg \u0026 Company, P.A.), advisory approval of executive compensation, approval of a reverse stock split (1-for-10 to 1-for-30 ratio) with authorized share reduction, and two amendments to the 2022 Omnibus Incentive Plan. All proposals passed. The reverse stock split authorization and equity plan amendments are material governance and capital structure decisions affecting shareholders.","company_name":"GT Biopharma, Inc.","ticker":"GTBP","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":29712,"accession_number":"0001493152-26-038446","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses results of GT Biopharma's Annual Meeting of Stockholders held on August 14, 2026, under Item 5.07. Six proposals were voted upon: election of four directors, ratification of auditors (Weinberg \u0026 Company, P.A.), advisory approval of executive compensation, approval of a reverse stock split (1-for-10 to 1-for-30 ratio) with authorized share reduction, and two amendments to the 2022 Omnibus Incentive Plan. All proposals passed. The reverse stock split authorization and equity plan amendments are material governance and capital structure decisions affecting shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:41:21.153936+00:00","company_name":"GT Biopharma, Inc.","ticker":"GTBP","filing_date":"2026-08-14"}]}